Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
about
Future of coagulation factor replacement therapyFc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasRecombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A miceTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AExpression and characterization of a codon-optimized blood coagulation factor VIII.Co-opting biology to deliver drugsA single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.Balancing the Expression and Production of a Heterodimeric Protein: Recombinant Agkisacutacin as a Novel Antithrombotic Drug CandidateRecombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.Generation and Characterization of an IgG4 Monomeric Fc Platform.Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.Progress toward inducing immunologic tolerance to factor VIII.Receptor-mediated endocytosis and brain delivery of therapeutic biologics.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Novel products for haemostasis - current status.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Industrial production of clotting factors: Challenges of expression, and choice of host cells.Half-life extended biotherapeutics.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.Efmoroctocog Alfa: A Review in Haemophilia A.2017 Clinical trials update: Innovations in hemophilia therapy.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Enhanced Proteolytic Processing of Recombinant Human Coagulation Factor VIII B-Domain Variants by Recombinant Furins.Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
P2860
Q26820824-AC12267B-6EBE-4DB1-BF37-D5189C938F7AQ27014771-60BFAFD1-EFC7-492A-B693-2008F723A773Q27321626-1C8011D3-C2A3-4B03-932C-A5CF6EF66BC3Q28075081-8A33ADAE-7070-4DB7-8E53-AB229CD706AEQ30397756-74DB9AB7-3477-4F4D-A671-5A1778C4C18AQ34424045-13941EF6-0AB4-4BB4-B85D-82B83AE497A6Q34557556-9D565883-6871-4FF7-B9CA-E8E5A14B62EBQ35168244-7D736254-FA21-4BA0-9B16-700E8E287392Q35565320-318C4B7A-947F-478B-AB28-F4871CEF0DB1Q35612397-70DD3AC5-F207-4294-AC90-02487E95C1B1Q35779980-4BCE9525-C023-4A8C-8B76-0EB98711E633Q35819141-3A68952F-8CA2-46DA-9DAE-3E730272B272Q35913495-17F7C9FC-9A9C-4E30-ABAA-F4ADD60F0658Q36091637-395E7B2F-95CF-42EA-BBE6-84EF9A6F9632Q37489013-4816DD96-9CD9-489A-997E-AEB4D6DF868AQ37494846-DCA02262-FF58-4425-9F3B-BBF3EDE33E81Q37614115-212A38DB-4229-400E-99A5-203F8B534456Q38090391-C713A973-77C9-444F-BAAF-280DF497FDF3Q38120524-32205266-8C3C-4068-B3C7-09243BF86105Q38127745-712642D7-3A5F-4D91-8A86-4A596D39A249Q38206849-408286E9-9688-4FA7-A9AA-B01EC791B30FQ38371071-A25EE424-C1CE-4265-BB9D-CA6B78EFA7BAQ38534584-82B36490-16B3-45D1-8F58-3F5CDE7EA9C9Q38770067-1034CB37-894D-491F-B22E-535241EC3607Q38828174-FB4C1E49-AAFF-41D2-92B8-652D4CFF7FB0Q38867485-F943B7CA-CDAF-477B-A577-EBCB8C89ADAAQ38883267-DE8DE194-1930-4B79-A073-2B3A0E7440E3Q38917306-A05F1235-716D-4B28-8DFF-222B75D7C32BQ38937725-92D25B0F-188B-41F1-A7DE-9ADF6E391035Q38944642-CC876559-1CED-4D80-B06E-EF74692931FEQ39204747-FF90BC39-040A-401D-94A3-19C4B275148EQ39475869-217BD271-2F31-42F7-90AB-3DB859739039Q39811881-B0E6EE8E-33D2-4837-9DC3-CC1F69C1E3DDQ40007308-943CB034-EDFB-4AD1-ACD9-C17FF5B55DDDQ40687307-A58AF2CB-5618-4E60-B979-C0678BDD6F4DQ41512058-75B865D4-FA18-4845-A6D5-E3B8612E9431Q41850873-2AA8E2AB-801D-4F6A-A9EF-E4F624F7B91CQ42971075-E5637524-095A-4E47-9CA6-8520B8B58FFCQ45855455-CEAAB9C9-1D91-4CE6-9692-AD4248BAAF96Q45857208-A7AF8CBC-72F0-4D24-AB39-F6F25318FA9D
P2860
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Biochemical and functional cha ...... factor VIII-Fc fusion protein
@en
type
label
Biochemical and functional cha ...... factor VIII-Fc fusion protein
@en
prefLabel
Biochemical and functional cha ...... factor VIII-Fc fusion protein
@en
P2093
P2860
P356
P1476
Biochemical and functional cha ...... factor VIII-Fc fusion protein
@en
P2093
A J Bitonti
G F Pierce
J D Kulman
R T Peters
P2860
P304
P356
10.1111/JTH.12076
P577
2013-01-01T00:00:00Z